MUC1 and Therapy Resistance in Pancreatic Cancer
Official title: MUC1 in Therapy Resistance
Funded at University of Oklahoma Hlth Sciences Ctr · NIH-11421836 · Data updated 2026-11-12
A patient-facing overview of how high MUC1 levels may make pancreatic cancer harder to treat and what the research hopes to learn.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | September 20, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $311,384 |
| NIH project number | 5U54CA274329-05 |
| Project ID | NIH-11421836 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with pancreatic cancer or cancers with high MUC1 expression could potentially benefit from advances arising from this research.
✕Less likely to help
If your cancer does not involve MUC1 overexpression, direct benefits from this project may be limited.
What this research studies
This project investigates why pancreatic cancer often resists therapy by studying MUC1, a protein that helps cancer cells survive. Researchers use laboratory studies to see how MUC1 changes cell signals and metabolism, and how it might help cancer cells withstand drugs like chemotherapy and radiation. The work aims to uncover new ideas for therapies that could overcome this resistance and improve outcomes for patients with pancreatic cancer. Results could guide future trials and personalized approaches based on MUC1 status.
Why it matters
Potential benefit: Understanding MUC1-driven resistance could lead to new treatments that make pancreatic cancer more responsive to therapy.
How similar studies have gone: Prior work has linked MUC1 to therapy resistance in multiple cancers, with some strategies showing promise in overcoming this resistance in preclinical models.
Where this research is happening
-
University of Oklahoma Hlth Sciences Ctr
Oklahoma City, United States Active
Researchers
- Principal investigator: Hollingsworth, Michael a. — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Hollingsworth, Michael a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.